USA flag logo/image

An Official Website of the United States Government

Identification of anti-inflammatory compounds from chocolate for the treatment…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43DE022475
Solicitation Year:
2012
Solicitation Topic Code:
NIDCR
Solicitation Number:
PA11-096
Small Business Information
THEO CHOCOLATE, INC.
3400 PHINNEY AVE N SEATTLE, WA 98103-8624
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Identification of anti-inflammatory compounds from chocolate for the treatment of
Agency: HHS
Contract: 1R43DE022475-01
Award Amount: $163,511.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this Phase 1 SBIR application is to identify and structurally characterize compounds in chocolate that could be used to treat tissue inflammation associated with gingivitis and periodontitis. Previous studies have demonstrated that water soluble extracts of cocoa bean husks and chocolate can contain activity that is either anti-inflammatory and/or dental plaque inhibiting. However, these extracts are practically unpalatable, a significant limitation for an oral formulation. Controlled evaluation of the structure-function relationships of potentially useful compounds arising during the chocolate manufacturing process has not been performed. In this proposal, extracts of characterized cocoa samples with known origin, fermentation profiles and specific heat treatment steps will be subjected to analytical characterization and preparative chromatographic separation and screened for the inhibition of Nf-kB activation in a mammalian cell line induced by lipopolysaccharides derived from Fusobacterium nucleatum. Fractions of chocolate extracts exhibiting Nf-kB antagonistic activity will be subject to initial characterization by mass spectrometry, and further separated to ensure that single chemical species are responsible for the observed activity. This Phase 1 research will lead to a Phase 2 project, where identified structures will be further characterized with respect to their mechanism of action and evaluated for their incorporation into a novel gum or mouthwash as anovel, safe, efficacious and cost-effective intervention for gingivitis and periodontitis. PUBLIC HEALTH RELEVANCE: Periodontal and gingival disease affects the majority of adults, can lead to tooth loss and has been associated with increased risks of cardiovascular disease and preterm birth, two conditions with high morbidity and mortality. There is compelling scientific evidence that extracts of cocoa display anti-inflammatory and dental plaque inhibiting characteristics but these chemistries areunpalatable for oral formulations. We propose a comprehensive evaluation of potentially useful compounds, with better flavor characteristics, generated during the chocolate manufacturing process that will lead to a better understanding of the therapeuticpotential for cocoa in oral health applications and the development of products to prevent and control gingivitis and periodontitis.

Principal Investigator:

Andy Mcshea
206-778-4526
amcshea@theochocolate.com

Business Contact:

Andy Mcshea
206-778-4526
amcshea@theochocolate.com
Small Business Information at Submission:

THEO CHOCOLATE, INC.
3400 PHINNEY AVE N SEATTLE, WA 98103-8624

EIN/Tax ID: 120488678
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No